Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Receivables (2016 - 2023)

Avalo Therapeutics' Receivables history spans 8 years, with the latest figure at $44000.0 for Q2 2023.

  • For Q2 2023, Receivables fell 97.62% year-over-year to $44000.0; the TTM value through Jun 2023 reached $44000.0, down 97.62%, while the annual FY2022 figure was $1.0 million, 79.16% down from the prior year.
  • Receivables reached $44000.0 in Q2 2023 per AVTX's latest filing, down from $1.9 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $8.2 million in Q1 2019 to a low of $44000.0 in Q2 2023.
  • Average Receivables over 5 years is $3.9 million, with a median of $4.3 million recorded in 2020.
  • Peak YoY movement for Receivables: soared 185.85% in 2019, then crashed 97.62% in 2023.
  • A 5-year view of Receivables shows it stood at $5.2 million in 2019, then decreased by 16.35% to $4.4 million in 2020, then grew by 9.44% to $4.8 million in 2021, then tumbled by 60.01% to $1.9 million in 2022, then tumbled by 97.71% to $44000.0 in 2023.
  • Per Business Quant, the three most recent readings for AVTX's Receivables are $44000.0 (Q2 2023), $1.9 million (Q4 2022), and $1.3 million (Q3 2022).